Monkeypox future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Bassel Almarie M.D.[2]

Overview

Countries are developing policies to define high risk groups to receive vaccines. Clinical investigations will be running to evaluate the appropriateness of vaccination to contain the outbreak^[1].

Future or investigational therapies

Countries are developing policies to define high risk groups to receive vaccines. Clinical investigations will be running to evaluate the appropriateness of vaccination to contain the outbreak^[1].

Antiviral agents such as Cidofovir or Tecovirimat were evaluated only for safety but not efficacy on human models. Future trials may evaluate the drug’s effectiveness to treat humans cases of monkeypox^[2]^[3]^[4].

In 2022, most cases in non-endemic areas had no travel association to endemic areas and were among men who have sex with men. It is hypothesized that monkeypox can be a sexuality transmitted^[5]^[6]. The role of semen and vaginal fluids in the transmission of monkeypox is being investigated^[7].

References

↑ ^1.0 ^1.1 “Monkeypox”. Retrieved 2022-06-16.
↑ De Clercq E (2002). “Cidofovir in the treatment of poxvirus infections”. Antiviral Res. 55 (1): 1–13. doi:10.1016/s0166-3542(02)00008-6. PMID 12076747.
↑ Jordan R, Tien D, Bolken TC, Jones KF, Tyavanagimatt SR, Strasser J; et al. (2008). “Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor”. Antimicrob Agents Chemother. 52 (5): 1721–7. doi:10.1128/AAC.01303-07. PMC 2346641. PMID 18316519.
↑ Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Leeds JM, Bolken TC, Jones KF; et al. (2012). “Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers”. Antimicrob Agents Chemother. 56 (9): 4900–5. doi:10.1128/AAC.00904-12. PMC 3421894. PMID 22777041.
↑ Bragazzi NL, Kong JD, Mahroum N, Tsigalou C, Khamisy-Farah R, Converti M, Wu J (June 2022). “Epidemiological trends and clinical features of the ongoing monkeypox epidemic: a preliminary pooled data analysis and literature review”. Journal of Medical Virology. doi:10.1002/jmv.27931. PMID 35692117 Check |pmid= value (help). |access-date= requires |url= (help)
↑ Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, Osborne JC, Rampling T, Beadsworth MB, Duncan CJ, Dunning J, Fletcher TE, Hunter ER, Jacobs M, Khoo SH, Newsholme W, Porter D, Porter RJ, Ratcliffe L, Schmid ML, Semple MG, Tunbridge AJ, Wingfield T, Price NM (May 2022). “Clinical features and management of human monkeypox: a retrospective observational study in the UK”. [[]]. doi:10.1016/S1473-3099(22)00228-6. |access-date= requires |url= (help)
↑ “U.S. Monkeypox Outbreak 2022: Situation Summary | Monkeypox | Poxvirus | CDC”.

[urlMonkeypox-1] 1.0 ^1.1 “Monkeypox”. Retrieved 2022-06-16.

[pmid12076747-2] De Clercq E (2002). “Cidofovir in the treatment of poxvirus infections”. Antiviral Res. 55 (1): 1–13. doi:10.1016/s0166-3542(02)00008-6. PMID 12076747.

[pmid18316519-3] Jordan R, Tien D, Bolken TC, Jones KF, Tyavanagimatt SR, Strasser J; et al. (2008). “Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor”. Antimicrob Agents Chemother. 52 (5): 1721–7. doi:10.1128/AAC.01303-07. PMC 2346641. PMID 18316519.

[pmid22777041-4] Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Leeds JM, Bolken TC, Jones KF; et al. (2012). “Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers”. Antimicrob Agents Chemother. 56 (9): 4900–5. doi:10.1128/AAC.00904-12. PMC 3421894. PMID 22777041.

[pmid35692117-5] Bragazzi NL, Kong JD, Mahroum N, Tsigalou C, Khamisy-Farah R, Converti M, Wu J (June 2022). “Epidemiological trends and clinical features of the ongoing monkeypox epidemic: a preliminary pooled data analysis and literature review”. Journal of Medical Virology. doi:10.1002/jmv.27931. PMID 35692117 Check |pmid= value (help). |access-date= requires |url= (help)

[pmid-6] Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, Osborne JC, Rampling T, Beadsworth MB, Duncan CJ, Dunning J, Fletcher TE, Hunter ER, Jacobs M, Khoo SH, Newsholme W, Porter D, Porter RJ, Ratcliffe L, Schmid ML, Semple MG, Tunbridge AJ, Wingfield T, Price NM (May 2022). “Clinical features and management of human monkeypox: a retrospective observational study in the UK”. [[]]. doi:10.1016/S1473-3099(22)00228-6. |access-date= requires |url= (help)

[urlU.S._Monkeypox_Outbreak_2022:_Situation_Summary_|_Monkeypox_|_Poxvirus_|_CDC-7] “U.S. Monkeypox Outbreak 2022: Situation Summary | Monkeypox | Poxvirus | CDC”.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

Monkeypox future or investigational therapies

Overview

Future or investigational therapies

References

Looking for the patient version?